Efficacy and safety of semaglutide in type 2 diabetes compared with sitagliptin, exenatide ER, insulin glargine, basal insulin and placebo: a systematic review | Zendy

Wei Lin | Zendy; Naeti Suksomboon | Zendy

Open Access

Efficacy and safety of semaglutide in type 2 diabetes compared with sitagliptin, exenatide ER, insulin glargine, basal insulin and placebo: a systematic review

Author(s) -

Wei Lin,

Naeti Suksomboon

Publication year - 2018

Publication title -

deleted journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.144

H-Index - 3

ISSN - 2586-8195

DOI - 10.29090/psa.2018.03.123

Subject(s) - sitagliptin , exenatide , insulin glargine , medicine , semaglutide , basal insulin , type 2 diabetes , placebo , dulaglutide , insulin , endocrinology , diabetes mellitus , liraglutide , alternative medicine , pathology

It is estimated that 415 million people have diabetes worldwide1. It is expected to rise to 592 million in 20352. Diabetes mellitus is not only chronic disease, but also brings a variety of complications, such as diabetic retinopathy. The glucagon-like peptide 1 receptor agonists (GLP-1 RAs) mimic the effects of endogenous GLP-1 hormone, stimulate insulin secretion and suppress glucagon secretion (in a glucose-dependent manner). GLP-1 RAs manage glycemic condition and stimulate satiety, as a result reducing food intake and body weight3. Currently, there are two types of GLP-1 RAs namely short-acting (such as exenatide, lixisenatide) and long-acting (such as liraglutide, dulaglutide, semaglutide) for the treatment of type 2 diabetes mellitus (T2DM). Subcutaneous semaglutide is a new

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research